Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.

ABSTRACT:

Objective

Plasma interleukin-1 beta may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of recombinant human interleukin-1 receptor antagonist by baseline plasma interleukin-1 beta or interleukin-1 receptor antagonist concentration.

Design

Retrospective subgroup analysis of randomized controlled trial.

Setting

Multicenter North American and European clinical trial.

Patients

Five hundred twenty-nine subjects with sepsis and hypotension or hypoperfusion, representing 59% of the original trial population.

Interventions

Random assignment of placebo or recombinant human interleukin-1 receptor antagonist × 72 hours.

Measurem

SUBMITTER: Meyer NJ 

PROVIDER: S-EPMC5734955 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature